DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $549,293 | +2.7% | 2,214 | -0.7% | 0.12% | +9.7% |
Q2 2023 | $534,960 | -4.8% | 2,229 | 0.0% | 0.11% | -9.6% |
Q1 2023 | $561,797 | -5.0% | 2,229 | 0.0% | 0.12% | -9.4% |
Q4 2022 | $591,621 | +8.4% | 2,229 | +5.4% | 0.14% | +1.5% |
Q3 2022 | $546,000 | -1.6% | 2,115 | -3.4% | 0.14% | +9.7% |
Q2 2022 | $555,000 | -14.4% | 2,190 | -0.9% | 0.12% | +4.2% |
Q1 2022 | $648,000 | -10.9% | 2,210 | 0.0% | 0.12% | -1.7% |
Q4 2021 | $727,000 | +6.4% | 2,210 | -1.4% | 0.12% | 0.0% |
Q3 2021 | $683,000 | +3.3% | 2,242 | -9.0% | 0.12% | +4.3% |
Q2 2021 | $661,000 | +24.5% | 2,464 | +4.5% | 0.12% | +12.6% |
Q1 2021 | $531,000 | +1.3% | 2,357 | 0.0% | 0.10% | -2.8% |
Q4 2020 | $524,000 | -4.0% | 2,357 | -7.1% | 0.11% | -13.8% |
Q3 2020 | $546,000 | +21.6% | 2,537 | 0.0% | 0.12% | +10.8% |
Q2 2020 | $449,000 | +27.9% | 2,537 | 0.0% | 0.11% | 0.0% |
Q1 2020 | $351,000 | -14.8% | 2,537 | -5.6% | 0.11% | +5.7% |
Q4 2019 | $412,000 | -10.8% | 2,687 | -16.0% | 0.10% | -22.8% |
Q3 2019 | $462,000 | -1.9% | 3,197 | -3.0% | 0.14% | +4.6% |
Q2 2019 | $471,000 | +5.1% | 3,297 | -2.9% | 0.13% | +1.6% |
Q1 2019 | $448,000 | +28.0% | 3,397 | 0.0% | 0.13% | +4.1% |
Q4 2018 | $350,000 | -7.7% | 3,397 | -2.5% | 0.12% | +35.2% |
Q3 2018 | $379,000 | +3.0% | 3,485 | -6.6% | 0.09% | -14.2% |
Q2 2018 | $368,000 | -2.6% | 3,730 | -3.6% | 0.11% | -7.0% |
Q1 2018 | $378,000 | 0.0% | 3,870 | -4.9% | 0.11% | -8.8% |
Q4 2017 | $378,000 | +8.3% | 4,070 | 0.0% | 0.12% | +5.9% |
Q3 2017 | $349,000 | -5.7% | 4,070 | -7.1% | 0.12% | -0.8% |
Q2 2017 | $370,000 | -5.6% | 4,380 | -4.4% | 0.12% | -16.8% |
Q1 2017 | $392,000 | +9.8% | 4,580 | 0.0% | 0.14% | +13.5% |
Q4 2016 | $357,000 | -0.6% | 4,580 | 0.0% | 0.13% | -0.8% |
Q3 2016 | $359,000 | -33.6% | 4,580 | -14.6% | 0.13% | -36.2% |
Q2 2016 | $541,000 | +4.6% | 5,360 | -1.6% | 0.20% | +10.6% |
Q1 2016 | $517,000 | -37.4% | 5,445 | -38.8% | 0.18% | -36.6% |
Q4 2015 | $826,000 | +15.5% | 8,895 | +6.0% | 0.28% | -3.4% |
Q3 2015 | $715,000 | +90.2% | 8,395 | +91.0% | 0.29% | +108.5% |
Q2 2015 | $376,000 | -2.8% | 4,395 | -3.6% | 0.14% | -0.7% |
Q1 2015 | $387,000 | +4.0% | 4,560 | +5.2% | 0.14% | +2.2% |
Q4 2014 | $372,000 | +12.4% | 4,335 | -0.6% | 0.14% | +11.2% |
Q3 2014 | $331,000 | -3.5% | 4,360 | 0.0% | 0.12% | -6.7% |
Q2 2014 | $343,000 | -99.9% | 4,360 | -6.4% | 0.13% | -9.5% |
Q1 2014 | $349,500,000 | +36845.0% | 4,660 | -62.0% | 0.15% | -62.8% |
Q4 2013 | $946,000 | +17.1% | 12,260 | +5.1% | 0.40% | +5.3% |
Q3 2013 | $808,000 | +3.3% | 11,660 | -5.7% | 0.38% | -10.4% |
Q2 2013 | $782,000 | – | 12,360 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |